Elie Dib: Talazoparib Confirmed Promising Activity in Solid Tumors With ATM Alterations
Elie Dib, Associate Director of the Haematology-Oncology Training Program at Saint Joseph Mercy Hospital, shared a post on LinkedIn:
“Excited to share results from the TAPUR study presented at AACR2025! Talazoparib confirmed promising activity in solid tumors with ATM alterations.
Immense gratitude to Trinity Health and the incredible medical team, along with all collaborating investigators!
This phase II basket study gives hope to patients with various advanced cancers who have limited treatment options.
Proud of everyone’s dedication to advancing targeted therapies! “
Title: Abstract CT228: Talazoparib (Tala) in patients (pts) with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Authors: Elie G. Dib; Michael Rothe; Pam K. Mangat; Elizabeth Garrett-Mayer; Dustin Bivins; Mark Gitau; Apar K. Ganti; Arthur Winer; Vijay Suhag; Darryl Outlaw; Michael J. Hall; Olatunji B. Alese; Reza Nazemzadeh; Evan Pisick; Fengting Yan; Navid Hafez; Carmen J. Calfa; Lex Leonhardt; David DeRemer; Abigail Gregory; Dominique C. Hinshaw; Gina N. Grantham; Susan Halabi; Richard L. Schilsky
You can read the Full Article on Cancer Research.
More posts featuring Elie Dib.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023